BioAtla, Inc. Share Price
BCABBioAtla, Inc. Stock Performance
Open $3.60 | Prev. Close $3.74 | Circuit Range N/A |
Day Range $3.60 - $3.63 | Year Range $0.12 - $6.13 | Volume 726 |
Average Traded $3.60 |
BioAtla, Inc. Share Price Chart
About BioAtla, Inc.
BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC to treat melanoma and squamous cell carcinoma of head and neck. It is also developing Evalstotug (BA3071), a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for treating melanoma, renal cell carcinoma, colorectal cancer, and NSCLC; BA3182, a bispecific candidate to treat adenocarcinomas; BA3361, a CAB-Nectin-4-ADC for treating tumors; BA3142, a dual-CAB T-cell engager targeting B7-H3, a protein expressed on various solid tumors; and preclinical candidate for CAB-Nectin 4 x CAB-CD3. The company was founded in 2007 and is headquartered in San Diego, California.
BioAtla, Inc. Historical Data
| Day | Open | Close | Change % |
|---|---|---|---|
20-May-26 | $3.61 | $3.74 | -3.73% |
19-May-26 | $3.42 | $3.88 | -3.72% |
18-May-26 | $4.25 | $4.04 | -8.61% |
15-May-26 | $4.42 | $4.42 | -1.78% |
14-May-26 | $4.50 | $4.50 | +0.56% |
12-May-26 | $4.63 | $4.47 | -0.89% |
11-May-26 | $4.62 | $4.51 | +1.81% |
FAQs on BioAtla, Inc. Share Price
Can I buy BioAtla, Inc. shares in India?
What is the share price of BioAtla, Inc.?
What is the 5 year returns of BioAtla, Inc.?
What are the high & low stock price of BioAtla, Inc. today?
What is the 52-week high and low of BioAtla, Inc. stock?